L11 and LR: Ameliorate Obesity via AMPK Pathway.

Objectives: The purpose of this study was to find the potential mechanism of two Lactobacillus ( L11 and LR) on ameliorating obesity, including lipid metabolism and gut microbiota. The two isolates have been studied to have good characterization in vitro, but in vivo studies in modulating lipid metabolism and gut microbiota were not studied.

Methods: In this study, mice with HFD supplemented with L11 or LR exhibited slower obesity progression, including reduced weight gain, abdominal fat accumulation, liver damage, inflammation, and adipose lesions.

Study on the Chemical Composition and Multidrug Resistance Reversal Activity of (Euphorbiaceae).

belongs to the family Euphorbiaceae and is widely distributed in northern Xinjiang, making it a characteristic plant of the region in Xinjiang, China. The chemical composition and biological activity of have not yet been reported, although certain compounds isolated from plants in Xinjiang, China, have demonstrated exceptional multidrug resistance (MDR) reversal. This study aims to investigate the chemical components present in with the potential to reverse MDR.

New Strategy for Microbial Corrosion Protection: Photocatalytic Antimicrobial Quantum Dots.

Microbial corrosion has significant implications for the economy, environment, and human safety worldwide. Photocatalytic antibacterial technology, owing to its advantages in environmental protection, broad-spectrum, and efficient sterilization, presents a compelling alternative to traditional antibacterial strategies for microbial corrosion protection. In recent years, photocatalytic quantum dot materials have garnered considerable attention in this field due to their unique quantum effects.

Efficacy and safety of first-line sintilimab plus anlotinib versus chemotherapy for metastatic non-small cell lung cancer: a phase II, open-label, randomized controlled trial.

Background: The prognosis for non-small cell lung cancer (NSCLC) patients treated with standard platinum-based chemotherapy was suboptimal, with safety concerns. Following encouraging results from a preliminary phase I study, this phase II trial investigated the efficacy and safety of first-line sintilimab and anlotinib in metastatic NSCLC.

Methods: In this open-label, randomized controlled trial (NCT04124731), metastatic NSCLC without epithelial growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or proto-oncogene tyrosine-protein kinase ROS (ROS1) mutations, and previous treatments for metastatic disease were enrolled.